{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:29:37Z","timestamp":1791286177656,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1053\/j.ajkd.2004.01.012","type":"journal-article","created":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T11:16:28Z","timestamp":1082978188000},"page":"877-890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4"],"prefix":"10.1053","volume":"43","author":[{"given":"Jack W","family":"Coburn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hla M","family":"Maung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Elangovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart M","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supp","key":"10.1053\/j.ajkd.2004.01.012_BIB1","first-page":"S171","article-title":"Ratio of parathyroid hormone to 1,25-dihydroxycholecalciferol in early renal failure","volume":"16","author":"Lucas","year":"1983","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem-67-5-876","article-title":"Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure","volume":"67","author":"Pitts","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ndt\/6.3.162","article-title":"Calcium metabolism in early chronic renal failure","volume":"6","author":"Reichel","year":"1991","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2004.01.012_BIB4","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/ndt\/11.supp3.22","article-title":"A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism","volume":"11","author":"Martinez","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.me.43.020192.001303","article-title":"The use of 1,25-dihydroxyvitamin D3 in early renal failure","volume":"43","author":"Goodman","year":"1992","journal-title":"Ann Rev Med"},{"issue":"suppl 4","key":"10.1053\/j.ajkd.2004.01.012_BIB6","first-page":"S71","article-title":"Prevention of metabolic bone disease in the pre-end-stage renal disease setting","volume":"9","author":"Coburn","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl","key":"10.1053\/j.ajkd.2004.01.012_BIB7","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1046\/j.1523-1755.63.s85.12.x","article-title":"Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4","volume":"63","author":"Coburn","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1210\/jcem-67-5-929","article-title":"Low dose calcitriol versus placebo in patients with predialysis chronic renal failure","volume":"67","author":"Nordal","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB9","series-title":"Vitamin D","first-page":"935","article-title":"Assessment of 1,25(OH)2D3 in the correction and prevention of renal osteodystrophy in patients with mild to moderate renal failure","author":"Massry","year":"1985"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3 administration in moderate renal failure","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000188515","article-title":"Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure","volume":"69","author":"Przedlacki","year":"1995","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(78)92702-2","article-title":"Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol","volume":"2","author":"Christiansen","year":"1978","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.0954-6820.1982.tb01901.x","article-title":"1,25(OH)2D3 and renal function","volume":"211","author":"Jensen","year":"1982","journal-title":"Acta Med Scand"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB15","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/ndt\/10.12.2228","article-title":"Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)","volume":"10","author":"Ritz","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1172\/JCI114229","article-title":"The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion","volume":"84","author":"Brown","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25(OH)2D3, 19-nor-1,25(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0003-9861(78)90475-7","article-title":"Biological activity of 1\u03b1-hydroxyvitamin D2 in the rat","volume":"186","author":"Reeve","year":"1978","journal-title":"Arch Biochem Biophys"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s002239900261","article-title":"1\u03b1-Hydroxyvitamin D2 partially dissociates between preservation of cancellous bone mass and effects on calcium homeostasis in ovariectomized rats","volume":"60","author":"Erben","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB20","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-\u03b1-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1\u03b1-hydroxyvitamin D2) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/ajkd.2001.22077","article-title":"Efficacy and side-effects of intermittent intravenous and oral doxercalciferol (1\u03b1-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism","volume":"37","author":"Maung","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(00)70198-3","article-title":"Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism","volume":"35","author":"Tsukamoto","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2004.01.012_BIB25","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines for Chronic Kidney Disease","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB26","first-page":"375","article-title":"Treatment of secondary hyperparathyroidism of pre-dialysis chronic renal failure with low doses of 1,25(OH)2D3","volume":"12","author":"Coen","year":"1986","journal-title":"Miner Electrolyte Metab"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB27","first-page":"1595","article-title":"Calcitriol and calcium carbonate therapy in early chronic renal failure","volume":"9","author":"Bianchi","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000186960","article-title":"Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure","volume":"61","author":"St John","year":"1992","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00302067","article-title":"Intact parathyroid hormone levels in renal insufficiency","volume":"57","author":"Fajtova","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB30","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/jn\/114.11.2043","article-title":"Antirachitic activity of 1\u03b1-hydroxyergocalciferol and 1\u03b1-hydroxycholecalciferol in rats","volume":"114","author":"Sj\u00f6den","year":"1984","journal-title":"J Nutr"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","article-title":"1\u03b1-Hydroxyvitamin D2 is less toxic than 1\u03b1-hydroxyvitamin D3 in the rat","volume":"178","author":"Sj\u00f6den","year":"1985","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jbmr.5650090504","article-title":"Effects of increasing doses of 1\u03b1-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women","volume":"9","author":"Gallagher","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB33","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1172\/JCI108424","article-title":"Comparison of effects of 1\u03b1-hydroxyvitamin D3 and 1,25-dihydroxy-vitamin D3 in man","volume":"57","author":"Brickman","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB34","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.1986.37","article-title":"Relationship between urinary calcium and calcium intake during calcitriol administration","volume":"29","author":"Smothers","year":"1986","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(78)91530-1","article-title":"Impairment of renal function in patients on 1\u03b1-hydroxycholecalciferol","volume":"2","author":"Winterborn","year":"1978","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB36","first-page":"98","article-title":"Renal function during calcitriol therapy in chronic renal failure","volume":"33","author":"Bertoli","year":"1990","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB37","first-page":"1070","article-title":"Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis","volume":"134","author":"Perez","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ki.1985.198","article-title":"Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up","volume":"28","author":"Coen","year":"1985","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB39","first-page":"145","article-title":"Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia","volume":"75","author":"Quarles","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ki.1993.64","article-title":"The spectrum of bone disease in end-stage renal failure\u2014An evolving disorder","volume":"43","author":"Sherrard","year":"1993","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-78-3-357","article-title":"Skeletal resistance to parathyroid hormone in renal failure","volume":"78","author":"Massry","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2004.01.012_BIB42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/ki.1976.42","article-title":"Bone histology in incipient and advanced renal failure","volume":"9","author":"Malluche","year":"1976","journal-title":"Kidney Int"}],"updated-by":[{"DOI":"10.1053\/j.ajkd.2004.04.016","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000}}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638604001416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638604001416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:24:29Z","timestamp":1759454669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638604001416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0272638604001416"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2004.01.012","relation":{"addendum":[{"id-type":"doi","id":"10.1053\/j.ajkd.2004.04.016","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2004.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}